SYNGR3 is a putative epigenetically-regulated gene with typical CpG features (defined as a region of ≥200 bp with ≥50% C + G and ≥0.6 CpG observed/CpG expected), which showed a significant 2.3-fold increase in the expression level after chemical-induced demethylation in human breast cancer MCF-7 cells [26]. This evidence concerns the gene SYNGR3 and breast carcinoma.